IMO-T 2.13 CGI-T -0.07 AC-T -0.05 LNR-T 1.37 LLY-N 2.04 META-Q 0.82 NVDA-Q -0.21
Daily Stock Opinions and Ratings
Stockchase Opinions

Peter Hodson Afexa Life Sciences Inc. FXA-T COMMENT Mar 12, 2007

A marketing company. A little bit of controversy. Want to label their product in the US. Never enthralled with marketing companies. Costs a lot of money and you are at the mercy of the vagueness of the consumer.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.490

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Afexa Life Sciences Inc.(FXA-T)

Dec 20, 2004
Stock has had a huge run. Huge growth opportunity.Product ColdFX seems to be working very well. Negative is that it is trading at about 31 X sales. Very high risk.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.510

Stock price when the opinion was issued

biotechnology pharmaceutical
WATCH

Afexa Life Sciences Inc.(FXA-T)

Feb 24, 2005
A very interesting company. Using ginseng extract to create a remedy for colds. (ColdFX) The product has just taken off. Still looking at it. If they go into the US, it could be a big boost. Might be a little expensive here.
Jean-Francois TardifJean-Francois Tardif
No
Unlock Rating
$2.630

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Afexa Life Sciences Inc.(FXA-T)

Mar 01, 2005
Great product. Watch for fads. Great marketing company.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.840

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Afexa Life Sciences Inc.(FXA-T)

Nov 02, 2006
Had a long drop from December to May which was followed by a number of upward steps. Those are very important levels and he thinks the stock probably has more positive news in it. Every time there is a rally, there is a lot of volume with it.
Jeff Parent B. Eng. FCSI CIMJeff Parent B. Eng. FCSI CIM
No
Unlock Rating
$3.980

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Afexa Life Sciences Inc.(FXA-T)

Dec 28, 2006
Started launching ColdFX in the US and want to go through the full trial process to get approval as to what they can claim on the product. Expensive stock.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.810

Stock price when the opinion was issued

biotechnology pharmaceutical
HOLD

Afexa Life Sciences Inc.(FXA-T)

Feb 26, 2007
Manufactures ColdFX. Loves the product, but a little concerned about the share price. Revenues are considerably smaller than the market cap. A little ahead of itself.
Michael DecterMichael Decter
No
Unlock Rating
$2.400

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

HRTG-N -0.007$18.863
EIF-T 0.37$48.84
MRK-N 0.35$78.35
MDI-T -0.11$8.3
DBM-T 0.03$6.86
Advertising

Today's Top Picks

IMO-T 2.13$88.37
CGI-T -0.07$33
AC-T -0.05$13.97
LNR-T 1.37$48.15
LLY-N 2.04$842

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

RH-N 0.12$161.25
LVMUY-… 0$109.54
NXPI-Q 0.18$170.92
DAL-N 0.07$40.92
AMD-Q -0.03$87.47

Most Recent Experts

Bruce Murray

The Murray Wealth Group

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Chris Blumas

at Raymond James Investment Counsel Ltd.

Stockchase Insights

5i Research

Advertising
Advertising
© Stockchase Inc.